Kara E. Boodhansingh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kara E. Boodhansingh has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Diva D. De Leon
Congenital Hyperinsulinism Center, Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia , Philadelphia, PA 19104
3 shared publications - Arupa Ganguly
Department of Human Genetics, Perelman School of Medicine at the University of Pennsylvania , Philadelphia, PA 19104
2 shared publications - Charles A. Stanley
Division of Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
2 shared publications - Christine Juliana
Congenital Hyperinsulinism Center, Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia , Philadelphia, PA 19104
2 shared publications - Lauren M. Mitteer
Congenital Hyperinsulinism Center, Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia , Philadelphia, PA 19104
2 shared publications - Tricia R. Bhatti
Department of Pathology, Children's Hospital of Philadelphia , Philadelphia, PA 19104
2 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , 2242-2250
Noncoding Variants in Intron 2 of HK1 Associated With Hyperinsulinism With Variable Clinical Phenotype
Introduction Non-coding variants in HK1 were first associated with congenital hyperinsulinism (HI) in a large family with diazoxide-responsive HI in 2008. Since then, additional cases have been reported in the literature with non-coding variants in HK1 associated with variable HI phenotypes. Methods We sequenced a 350bp region in intron 2 of HK1 in 281 individuals with genetics negative HI to identify additional cases related to non-coding HK1 variants and to characterize the clinical features of these cases. Results We identified 16 unique non-coding variants in intron 2 of HK1 in 18 individuals with genetics negative HI (18/281, 6.4%). In seven cases (7/18, 39%), the HK1 variant was inherited from a parent (2 maternal, 5 paternal), two are known to be affected with HI. In nine cases, the HK1 variant was de novo (9/18, 50%). The age of presentation of HI ranged from day of life one to 21 months of age. Seven cases had diazoxide-responsive HI (7/18, 39%). Eleven cases were diazoxide unresponsive (11/18, 61%); five underwent pancreatectomy at ages ranging from six months to three years of age. Conclusions Non-coding variants in intron 2 of the HK1 gene have now been associated with HI in a growing number of cases. Our findings suggest that a significant proportion of individuals with negative genetics in genes currently known to be associated with HI may harbor HK1 intron 2 variants. Identifying these cases is important for clinical care as well as for assessing recurrence risk for families.
- 10 March 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , 2242-2250
Open AccessNoncoding Variants in Intron 2 of HK1 Associated With Hyperinsulinism With Variable Clinical Phenotype
Introduction Non-coding variants in HK1 were first associated with congenital hyperinsulinism (HI) in a large family with diazoxide-responsive HI in 2008. Since then, additional cases have been reported in the literature with non-coding variants in HK1 associated with variable HI phenotypes. Methods We sequenced a 350bp region in intron 2 of HK1 in 281 individuals with genetics negative HI to identify additional cases related to non-coding HK1 variants and to characterize the clinical features of these cases. Results We identified 16 unique non-coding variants in intron 2 of HK1 in 18 individuals with genetics negative HI (18/281, 6.4%). In seven cases (7/18, 39%), the HK1 variant was inherited from a parent (2 maternal, 5 paternal), two are known to be affected with HI. In nine cases, the HK1 variant was de novo (9/18, 50%). The age of presentation of HI ranged from day of life one to 21 months of age. Seven cases had diazoxide-responsive HI (7/18, 39%). Eleven cases were diazoxide unresponsive (11/18, 61%); five underwent pancreatectomy at ages ranging from six months to three years of age. Conclusions Non-coding variants in intron 2 of the HK1 gene have now been associated with HI in a growing number of cases. Our findings suggest that a significant proportion of individuals with negative genetics in genes currently known to be associated with HI may harbor HK1 intron 2 variants. Identifying these cases is important for clinical care as well as for assessing recurrence risk for families.
- Open Access
- 15 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , 1874-1885
Functional evaluation of pancreatic islets from patients with Beckwith–Wiedemann syndrome and congenital hyperinsulinism
Context: Beckwith–Wiedemann Syndrome (BWS) is an overgrowth syndrome caused by various genetic or epigenetic abnormalities in a cluster of imprinted genes on chromosome 11p15. Congenital hyperinsulinism (HI) is one of the cardinal features of BWS, but the pathophysiology of HI in BWS has not been clearly defined. Objective: We describe the islet phenotype of a series of infants with severe HI and comorbid BWS who required pancreatectomy for intractable hypoglycemia. Methods: The cases are a subset of HI patients who required pancreatectomy and had Beckwith–Wiedemann Syndrome. Molecular testing for BWS was performed by SNP array and chromosome 11p15 methylation analysis. Functional analysis of insulin secretion in pancreatic islets isolated from pancreatectomy samples was completed with perifusion experiments and cytosolic Ca2+ measurements. Results: Similar to what we had previously described in islets isolated from the pancreas of infants with HI due to inactivating mutations in the KATP channel, BWS–HI islets have elevated concentrations of cytosolic calcium and secrete insulin in response to stimulation with a physiologic mixture of amino acids. However, unlike KATPHI islets, most BWS–HI islets retain responsiveness to stimulation with glucose and the KATP channel inhibitor glyburide. Through RNAseq analysis, we observed that expression of KCNQ1, encoding the pore-forming subunit of a voltage-gated K + channel (Kv7.1), is reduced in BWS–HI islets compared to normal human islets (3-fold; P = 4.5 × 10-7). Conclusion: Our expression analysis and functional evaluation of islets isolated from BWS–HI patients reveal the spectrum of insulin secretion responses found across BWS etiologies and suggest a potential role for loss of KCNQ1 expression in the complex pathophysiology responsible for the hyperinsulinism in BWS.
- 15 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , 1874-1885
Open AccessFunctional evaluation of pancreatic islets from patients with Beckwith–Wiedemann syndrome and congenital hyperinsulinism
Context: Beckwith–Wiedemann Syndrome (BWS) is an overgrowth syndrome caused by various genetic or epigenetic abnormalities in a cluster of imprinted genes on chromosome 11p15. Congenital hyperinsulinism (HI) is one of the cardinal features of BWS, but the pathophysiology of HI in BWS has not been clearly defined. Objective: We describe the islet phenotype of a series of infants with severe HI and comorbid BWS who required pancreatectomy for intractable hypoglycemia. Methods: The cases are a subset of HI patients who required pancreatectomy and had Beckwith–Wiedemann Syndrome. Molecular testing for BWS was performed by SNP array and chromosome 11p15 methylation analysis. Functional analysis of insulin secretion in pancreatic islets isolated from pancreatectomy samples was completed with perifusion experiments and cytosolic Ca2+ measurements. Results: Similar to what we had previously described in islets isolated from the pancreas of infants with HI due to inactivating mutations in the KATP channel, BWS–HI islets have elevated concentrations of cytosolic calcium and secrete insulin in response to stimulation with a physiologic mixture of amino acids. However, unlike KATPHI islets, most BWS–HI islets retain responsiveness to stimulation with glucose and the KATP channel inhibitor glyburide. Through RNAseq analysis, we observed that expression of KCNQ1, encoding the pore-forming subunit of a voltage-gated K + channel (Kv7.1), is reduced in BWS–HI islets compared to normal human islets (3-fold; P = 4.5 × 10-7). Conclusion: Our expression analysis and functional evaluation of islets isolated from BWS–HI patients reveal the spectrum of insulin secretion responses found across BWS etiologies and suggest a potential role for loss of KCNQ1 expression in the complex pathophysiology responsible for the hyperinsulinism in BWS.
- Open Access
- 28 August 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 179 (11) , 2214-2227
Novel dominant KATP channel mutations in infants with congenital hyperinsulinism: Validation by in vitro expression studies and in vivo carrier phenotyping
Inactivating mutations in the genes encoding the two subunits of the pancreatic beta‐cell KATP channel, ABCC8 and KCNJ11, are the most common finding in children with congenital hyperinsulinism (HI). Interpreting novel missense variants in these genes is problematic, because they can be either dominant or recessive mutations, benign polymorphisms, or diabetes mutations. This report describes six novel missense variants in ABCC8 and KCNJ11 that were identified in 11 probands with congenital HI. One of the three ABCC8 mutations (p.Ala1458Thr) and all three KCNJ11 mutations were associated with responsiveness to diazoxide. Sixteen family members carried the ABCC8 or KCNJ11 mutations; only two had hypoglycemia detected at birth and four others reported symptoms of hypoglycemia. Phenotype testing of seven adult mutation carriers revealed abnormal protein‐induced hypoglycemia in all; fasting hypoketotic hypoglycemia was demonstrated in four of the seven. All of six mutations were confirmed to cause dominant pathogenic defects based on in vitro expression studies in COSm6 cells demonstrating normal trafficking, but reduced responses to MgADP and diazoxide. These results indicate a combination of in vitro and in vivo phenotype tests can be used to differentiate dominant from recessive KATP channel HI mutations and personalize management of children with congenital HI.
- 28 August 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 179 (11) , 2214-2227
Open AccessNovel dominant KATP channel mutations in infants with congenital hyperinsulinism: Validation by in vitro expression studies and in vivo carrier phenotyping
Inactivating mutations in the genes encoding the two subunits of the pancreatic beta‐cell KATP channel, ABCC8 and KCNJ11, are the most common finding in children with congenital hyperinsulinism (HI). Interpreting novel missense variants in these genes is problematic, because they can be either dominant or recessive mutations, benign polymorphisms, or diabetes mutations. This report describes six novel missense variants in ABCC8 and KCNJ11 that were identified in 11 probands with congenital HI. One of the three ABCC8 mutations (p.Ala1458Thr) and all three KCNJ11 mutations were associated with responsiveness to diazoxide. Sixteen family members carried the ABCC8 or KCNJ11 mutations; only two had hypoglycemia detected at birth and four others reported symptoms of hypoglycemia. Phenotype testing of seven adult mutation carriers revealed abnormal protein‐induced hypoglycemia in all; fasting hypoketotic hypoglycemia was demonstrated in four of the seven. All of six mutations were confirmed to cause dominant pathogenic defects based on in vitro expression studies in COSm6 cells demonstrating normal trafficking, but reduced responses to MgADP and diazoxide. These results indicate a combination of in vitro and in vivo phenotype tests can be used to differentiate dominant from recessive KATP channel HI mutations and personalize management of children with congenital HI.
- 5 January 2019
- Published by Springer Nature
- p. 61-69
Molecular Diagnosis of Congenital Hyperinsulinism